Since serum β2-microglobulin increases with both higher tumor burden and diminished renal function, it was suggested that evaluation of β2-microglobulin levels may be useful before intravenous injection of iodinate contrast agents to patients with multiple myeloma [51]. This evidence concerns the gene HLA-G and neoplasm.